The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Impact of CheckMate-238 Results for Patients With Melanoma

Jeffrey S. Weber, MD, PhD
Published Online:3:31 PM, Mon September 18, 2017

Jeffrey S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses how results of the CheckMate-238 study will impact patients with melanoma.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.